Pharma’s Cutting Edge

Pharma’s Cutting Edge

Pharmaceutical and biotech science and business

 
 
 
 

F/U to 10-7 post on AMLN

On 10/7 I asked whether AMLN was setting up for a near-term fall based on faulty analyst estimates of first-quarter exenatide sales and the associated run-up in its price above its historical BTK tracking level. Well…it was and it did. It’s now trading at around its BTK tracking level again. If you got in for a short-term trade, now would be a good time to get out.

Leave a Reply

You must be logged in to post a comment.

Pages

Recent Posts

Pharma's Cutting Edge Archives

Categories

Meta

Blogroll

Syndicate

  • Subscribe to my feed